Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 1:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 62 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo Pen Injector Clear all
Completed Phase 3 Interventional Results available

Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)

NCT02023879
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Alirocumab, Placebo (for Alirocumab), Non-statin LMT, Diet Alone
Drug · Other
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
8
States / cities
Beverly Hills, California • Atlantis, Florida • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Sep 6, 2026, 1:27 AM EDT
Completed Phase 3 Interventional Results available

24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years

NCT00976937
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Lixisenatide (AVE0010), Lixisenatide Placebo, Pen auto-injector, Sitagliptin, Sitagliptin Placebo, Metformin
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 49 Years
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
21
States / cities
Montgomery, Alabama • Muscle Shoals, Alabama • Mesa, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2016 · Synced Sep 6, 2026, 1:27 AM EDT
Active, not recruiting Phase 3 Interventional

A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation

NCT05636176
View directory record Official record
Conditions
Heart Failure
Interventions
Ziltivekimab, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
4,899 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
172
States / cities
Alexander City, Alabama • Fairhope, Alabama • Huntsville, Alabama + 141 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 6, 2026, 1:27 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Triple Therapy in T1DM

NCT03899402
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin, Semaglutide, Dapagliflozin, Placebo to Dapagliflozin
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 75 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Williamsville, New York
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 6, 2026, 1:27 AM EDT
Completed Phase 3 Interventional Results available

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin

NCT00763451
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Lixisenatide (AVE0010), Placebo, Pen auto-injector, Metformin
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 13, 2016 · Synced Sep 6, 2026, 1:27 AM EDT
Recruiting Phase 3 Interventional

Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation

NCT06499857
View directory record Official record
Conditions
Overweight or Obesity, Atrial Fibrillation
Interventions
Semaglutide, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Phoenix, Arizona • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Sep 6, 2026, 1:27 AM EDT
Active, not recruiting Phase 2 Interventional

Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)

NCT05254314
View directory record Official record
Conditions
Asthma
Interventions
Semaglutide Pen Injector 2.4mg weekly, Placebo
Drug · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Sep 6, 2026, 1:27 AM EDT
Completed Phase 3 Interventional Results available

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea

NCT00713830
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Lixisenatide (AVE0010), Placebo, Pen auto-injector, Sulfonylurea, Metformin
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
859 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 13, 2016 · Synced Sep 6, 2026, 1:27 AM EDT
Recruiting Phase 3 Interventional

AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

NCT07533175
View directory record Official record
Conditions
Diabetes Mellitus, Overweight, Obesity
Interventions
NNC0487-0111, Placebo (matched to NNC0487-0111)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
15
States / cities
Birmingham, Alabama • Escondido, California • Lomita, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 6, 2026, 1:27 AM EDT
Withdrawn Phase 3 Interventional

A Study to Evaluate Pharmacokinetics, Safety and Efficacy of Albiglutide in Pediatric Subjects With Type 2 Diabetes Mellitus

NCT03015519
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Albiglutide, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
10 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Chicago, Illinois • Morehead City, North Carolina • El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Sep 6, 2026, 1:27 AM EDT
Terminated Phase 3 Interventional Results available

Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy

NCT04741074
View directory record Official record
Conditions
CKD, Diabetic Kidney Disease, Type 2 Diabetes Mellitus in Obese, Obesity, Severe Obesity
Interventions
Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution, Placebo 1.5 ml, prefilled pen-injector for subcutaneous injection solution
Drug
Lead sponsor
Geisinger Clinic
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Danville, Pennsylvania • Wilkes-Barre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced Sep 6, 2026, 1:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of Two Albiglutide Drug Products in Healthy Adult Subjects

NCT02660736
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Albiglutide Liquid Auto-injector, Albiglutide Lyophilized DCC Pen Injector, Placebo Liquid Auto-injector, Placebo Lyophilized DCC Pen injector
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 8, 2016 · Synced Sep 6, 2026, 1:27 AM EDT
Active, not recruiting Phase 3 Interventional

A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes

NCT03811561
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Semaglutide, Placebo (semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
72
States / cities
Phoenix, Arizona • Tucson, Arizona • Coronado, California + 54 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 6, 2026, 1:27 AM EDT
Recruiting Phase 2 Interventional

Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant

NCT05424003
View directory record Official record
Conditions
NAFLD
Interventions
Semaglutide Pen Injector, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 6, 2026, 1:27 AM EDT
Recruiting Phase 2 Interventional

The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes

NCT06976619
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
Liraglutide Pen Injector, Saline Injections
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 6, 2026, 1:27 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)

NCT01644175
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Placebo (for alirocumab), Alirocumab, Lipid-Modifying Therapy (LMT)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
76
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 68 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2015 · Synced Sep 6, 2026, 1:27 AM EDT
Completed Phase 3 Interventional Results available

GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin

NCT00712673
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Lixisenatide (AVE0010), Placebo, Pen auto-injector, Metformin
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Sep 6, 2026, 1:27 AM EDT
Active, not recruiting Phase 3 Interventional

Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide

NCT07220642
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Cagrilintide, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
9
States / cities
Walnut Creek, California • Aurora, Colorado • Orlando, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 6, 2026, 1:27 AM EDT
Not yet recruiting Phase 3 Interventional

A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide

NCT07668414
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Zenagamtide, Semaglutide, Placebo (matched to semaglutide), Placebo (matched to zenagamtide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
43
States / cities
Lancaster, California • Palm Springs, California • Pomona, California + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 6, 2026, 1:27 AM EDT
Completed Phase 2 Interventional

Abaloparatide and Pelvic Fracture Healing

NCT04249232
View directory record Official record
Conditions
Fracture of Pelvis (Disorder)
Interventions
Abaloparatide 80 micrograms per Pen dose, Placebo prefilled injector pen
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
50 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
New York, New York • Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Sep 6, 2026, 1:27 AM EDT
Recruiting Phase 2 Interventional

GLP-1R Agonist Treatment for Opioid Use Disorder

NCT06548490
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Abuse and Addiction, Narcotic-Related Disorders, Substance-Related Disorders, Chemically-Induced Disorders, Mental Disorder, Opioid
Interventions
Semaglutide Pen Injector, Placebo
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Baltimore, Maryland • Fall River, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 6, 2026, 1:27 AM EDT
Not yet recruiting Phase 2 Interventional

Semaglutide for Low Back Pain

NCT07731256
View directory record Official record
Conditions
Lower Back Pain, Obesity (BMI>30), Chronic Lower Back Pain, glp1 Agonist
Interventions
Semaglutide (administered by PDS290 pen-injector), Placebo (administered by PDS290 pen-injector)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 85 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
2
States / cities
Birmingham, Alabama • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 6, 2026, 1:27 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Impact of Liraglutide 3.0 on Body Fat Distribution

NCT03038620
View directory record Official record
Conditions
Obesity, Visceral, Cardiovascular Diseases, Fat Disorder
Interventions
Liraglutide, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
35 Years and older
Enrollment
235 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Sep 6, 2026, 1:27 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)

NCT01147250
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Lixisenatide (AVE0010), Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
30 Years and older
Enrollment
6,068 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
200
States / cities
Birmingham, Alabama • Foley, Alabama • Mobile, Alabama + 160 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2016 · Synced Sep 6, 2026, 1:27 AM EDT